Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.